Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.64 |
| ▸ | HTR1A | P08908 | 13/20 | 0.64 |
| ▸ | HTR2A | P28223 | 13/20 | 0.64 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD5 | P21918 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15546512 | 0.87 | DRD2 (0.53) | DRD2HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL15546694 | 0.86 | DRD2 (0.52) | DRD2HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL15601760 | 0.86 | DRD2 (0.52) | DRD2HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL15545082 | 0.86 | HTR1A (0.57) | DRD2HTR1AHTR2ADRD3HTR2B | |
| SCHEMBL20078464 | 0.85 | HTR1A (0.56) | DRD2HTR1AHTR2ADRD3HTR7 | |
| SCHEMBL15547087 | 0.82 | HTR1A (0.55) | DRD2HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL15601707 | 0.81 | DRD2 (0.53) | DRD2HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL15545407 | 0.81 | DRD2 (0.52) | DRD2HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL15545401 | 0.80 | DRD2 (0.68) | DRD2HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL16553287 | 0.80 | HTR1A (0.52) | DRD2HTR1AHTR2AHTR2CDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847193-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-01-31 | — | — | US | disclosed |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-01-31 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2847193-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2013169964-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072974-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | DRD2 53/4885HTR1A 24/4885HTR2A 16/4885 |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | DRD2 53/4885HTR1A 24/4885HTR2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.